ThromboGenics and BioInvent Announce Alliance with Roche
UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.
UVEN, Belgium-ThromboGenics NV and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche for their jointly developed anticancer agent TB-403, a novel monoclonal antibody that blocks PIGF, one of the growth factors responsible for angiogenesis.
Articles in this issue
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Articles
- Belantamab Exhibits Rapid/Prolonged Plasmablast Cell Reduction in Myeloma
September 20th 2025
- MRD Negativity Improves With Daratumumab Maintenance Combo in NDMM
September 20th 2025
- Managing AEs with Gemcitabine Intravesical System in NMIBC
September 20th 2025
- Sonrotoclax Combo Shows Safety, Promising Efficacy in R/R Multiple Myeloma
September 20th 2025
- P53 Mutations May Reveal Viability of Different Pancreatic Cancer Therapies
September 20th 2025